Acetyldigoxin
From Wikipedia, the free encyclopedia
 |
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (August 2007) |
 |
This article provides insufficient context for those unfamiliar with the subject. Please help improve the article with a good introductory style. (October 2009) |
 |
|
|---|---|
| Systematic (IUPAC) name | |
| [6-[6-[ [6-[ [12,14-dihydroxy-10,13-dimethyl-17- | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 90%(Oral) |
| Protein binding | 20-30% |
| Half-life | 40h |
| Identifiers | |
| CAS number | 5511-98-8 |
| ATC code | C01AA02 |
| PubChem | CID 11765960 |
| ChemSpider | 9940650  |
| UNII | P7K44M64CW |
| Chemical data | |
| Formula | C43H66O15 |
| Mol. mass | 822.975 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Acetyldigoxin is a cardiac glycoside. It is an acetyl derivative of digoxin. Its positive cardioinotropic effect starts after 3-4h and maximizes after 6-8h. It is prescribed for congestive chronic cardiac failure class II, III and IV from different reasons, tachysystolic form of fibrillation and proximal
|
||||||||||||||||||||||||||||||||
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
